Lindner Thomas, Altmann Annette, Giesel Frederik, Kratochwil Clemens, Kleist Christian, Krämer Susanne, Mier Walter, Cardinale Jens, Kauczor Hans-Ulrich, Jäger Dirk, Debus Jürgen, Haberkorn Uwe
Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.
EJNMMI Radiopharm Chem. 2021 Aug 21;6(1):26. doi: 10.1186/s41181-021-00144-x.
Cancer-associated fibroblasts are found in the stroma of epithelial tumors. They are characterized by overexpression of the fibroblast activation protein (FAP), a serine protease which was already proven as attractive target for chelator-based theranostics. Unfortunately, the value of gallium-68 labeled tracers is limited by their batch size and the short nuclide half-life. To overcome this drawback, radiolabeling with aluminum fluoride complexes and 6-fluoronicotinamide derivatives of the longer-lived nuclide fluorine-18 was established. The novel compounds were tested for their FAP-specific binding affinity. Uptake and binding competition were studied in vitro using FAP expressing HT-1080 cells. HEK cells transfected with the closely related dipeptidyl peptidase-4 (HEK-CD26) were used as negative control. Small animal positron emission tomography imaging and biodistribution experiments were performed in HT-1080-FAP xenografted nude mice. [F]AlF-FAPI-74 was selected for PET/CT imaging in a non-small cell lung cancer (NSCLC) patient.
In vitro, F-labeled FAPI-derivatives demonstrated high affinity (EC = < 1 nm to 4.2 nm) and binding of up to 80% to the FAP-expressing HT1080 cells while no binding to HEK-CD26 cells was observed. While small animal PET imaging revealed unfavorable biliary excretion of most of the F-labeled compounds, the NOTA bearing compounds [F]AlF-FAPI-74 and -75 achieved good tumor-to-background ratios, as a result of their preferred renal excretion. These two compounds showed the highest tumor accumulation in PET imaging. The organ distribution values of [F]AlF-FAPI-74 were in accordance with the small animal PET imaging results. Due to its less complex synthesis, fast clearance and low background values, [F]AlF-FAPI-74 was chosen for clinical imaging. PET/CT of a patient with metastasized non-small cell lung cancer (NSCLC), enabled visualization of the primary tumor and its metastases at the hepatic portal and in several bones. This was accompanied by a rapid clearance from the blood pool and low background in healthy organs.
[F]AlF-labeled FAPI derivatives represent powerful tracers for PET. Owing to an excellent performance in PET imaging, FAPI-74 can be regarded as a promising precursor for [F]AlF-based FAP-imaging.
癌症相关成纤维细胞存在于上皮肿瘤的基质中。它们的特征是成纤维细胞活化蛋白(FAP)过表达,FAP是一种丝氨酸蛋白酶,已被证明是基于螯合剂的诊疗一体化的有吸引力的靶点。不幸的是,镓-68标记的示踪剂的价值受到其批量大小和短核素半衰期的限制。为了克服这一缺点,建立了用氟化铝络合物和长寿命核素氟-18的6-氟烟酰胺衍生物进行放射性标记的方法。测试了这些新型化合物的FAP特异性结合亲和力。使用表达FAP的HT-1080细胞在体外研究摄取和结合竞争。转染了密切相关的二肽基肽酶-4(HEK-CD26)的HEK细胞用作阴性对照。在HT-1080-FAP异种移植裸鼠中进行小动物正电子发射断层扫描成像和生物分布实验。选择[F]AlF-FAPI-74用于一名非小细胞肺癌(NSCLC)患者的PET/CT成像。
在体外,F标记的FAPI衍生物表现出高亲和力(EC = <1nm至4.2nm),与表达FAP的HT1080细胞的结合率高达80%,而未观察到与HEK-CD26细胞的结合。虽然小动物PET成像显示大多数F标记化合物的胆汁排泄不理想,但带有NOTA的化合物[F]AlF-FAPI-74和-75由于其优先的肾脏排泄而获得了良好的肿瘤与背景比值。这两种化合物在PET成像中显示出最高的肿瘤蓄积。[F]AlF-FAPI-74的器官分布值与小动物PET成像结果一致。由于其合成不太复杂、清除快且背景值低,[F]AlF-FAPI-74被选用于临床成像。一名转移性非小细胞肺癌(NSCLC)患者的PET/CT能够显示原发性肿瘤及其在肝门和多处骨骼中的转移灶。这伴随着从血池的快速清除和健康器官中的低背景。
[F]AlF标记的FAPI衍生物是PET的强大示踪剂。由于在PET成像中表现出色,FAPI-74可被视为基于[F]AlF的FAP成像的有前景的前体。